ALT 240920 6.00C (ALT240920C6000) Stock Options, News & Quotes

US OptionsDetailed Quotes

ALT240920C6000

Watchlist

1.60
-0.20-11.11%

15min DelayTrading Sep 16 12:53 ET

1.79High1.60Low

Intraday

5D
Daily

News

Institutional Investors Control 60% of Altimmune, Inc. (NASDAQ:ALT) and Were Rewarded Last Week After Stock Increased 11%
Simply Wall StSep 13 06:45 ET
JMP Securities Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $24
Moomoo NewsSep 10 17:32 ET · Ratings
Buy Rating Affirmed for Altimmune on Pemvidutide's Positive Trial Data and Strategic Advancements
TipRanksSep 10 16:35 ET · Ratings
Altimmune Spikes After Presenting Data for Obesity Drug
Seeking AlphaSep 10 15:47 ET
Express News | Altimmune Corrects Previous Release; Says Reduction Of Visceral Adipose Tissue (VAT) At Week 48 Adjusted To 28.3% From 25.6%, And Subcutaneous Adipose Tissue Reduction Revised To 19.5% From 20.1%
BenzingaSep 10 13:14 ET
Altimmune Presents Data From Its Phase 2, MRI-Based Body Composition Sub-study Of Pemvidutide In Subjects With Overweight And Obesity
BenzingaSep 10 07:52 ET

Comments

Trytosaveabit

Sep 10 06:56

Update

$Altimmune (ALT.US)$ Altimmune Presents Data From Its Phase 2, MRI-Based Body Composition Sub-study Of Pemvidutide In Subjects With Overweight And Obesity
Benzinga· 1 min ago
In an MRI sub-study of 67 subjects from the Phase 2 MOMENTUM obesity trial, 50 of whom were treated with pemvidutide for 48 weeks, the lean loss ratio, defined as the change in lean mass compared to the change in total mass, was 21.9%.
Lean mass preservation was greater in subjects aged 60 years and older, in whom the ...

Jaguar8

Sep 10 06:46

NEWS

$Altimmune (ALT.US)$
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
Altimmune presented results from a Phase 2 MRI-based body composition sub-study of pemvidutide at the 60th Annual Meeting of the European Association for the Study of Diabetes. The study, involving 67 subjects from the MOMENTUM obesity trial, showed promising outcomes for pemvidutide, a novel GLP-1/glucagon dual receptor...

frogoracletrading

Aug 19 16:08

$ALT Support / Resistance Levels

Another strong day for ALT. 7.65 is resistance now. Support is at 7.40 the top of the POC.
Larger Image: tradingview.com...
$Altimmune (ALT.US)$

Meticulous Trader

Aug 19 13:07

$Altimmune (ALT.US)$ 👀looks food 1 month breakout
$Altimmune (ALT.US)$

frogoracletrading

Aug 19 11:22

$ALT Support / Resistance Levels

Pushing up into the POC now. Here are the levels to keep an eye on this week.
Larger Image: tradingview.com...
$Altimmune (ALT.US)$